A Phase 2 interventional study of Iptacopan in Immune Thrombocytopenia (ITP) and Cold Agglutinin Disease (CAD), sponsored by Novartis Pharmaceuticals. Terminated at 8 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 7th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals
Ages 5–17
By country, each count listing its studies:
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2021.
This study's enrollment of 19 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 39 across the 12 interventional studies, 150 across the 3 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Purpura, Thrombocytopenic, Idiopathic by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.
This was an open-label, single-arm (within each cohort), multi-center, non-confirmatory basket study to assess the efficacy, safety and pharmacokinetics of iptacopan in participants with autoimmune benign hematological disorders. The study was set up as a basket study to allow inclusion of new cohorts (indications). The study included 2 cohorts: primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). Participants in Cohort 1 (ITP) were stratified in two groups according to high/low complement activation (i.e., based on sC5b-9 level at screening). No additional cohorts were added during the study.
The study consisted of a screening period, a 12-week treatment period (Part A), a washout (for responders)/follow-up (for non-responders) period after Part A, and, for responders only, an additional treatment extension period for up to 24 months (Part B). Non-responders who had signs of clinical benefit according to the Investigator's assessment could also continue treatment with iptacopan in Part B. The washout period prior to the start of part B lasted up to 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Cohorts:
Cohort 1 specific inclusion criteria:
Cohort 2 specific inclusion criteria:
Exclusion Criteria:
All cohorts:
Cohort 1 specific exclusion criteria:
Cohort 2 specific exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iptacopan 200 mg twice daily (BID) in participants with primary ITP and primary CAD
Drug: Iptacopan
Iptacopan 200 mg BID given orally (capsule)
Also known as: Investigational new drug, company code: LNP023
Cohort 1 (ITP): Number of Participants With a Clinically Meaningful Response
A study participant with ITP was considered a responder if all the below criteria were met: 1. Platelet count of ≥50 k/μL sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat ITP 3. Lack of treatment discontinuation
Time frame: Up to 12 weeks (Part A)
Cohort 2 (CAD): Number of Participants With a Clinically Meaningful Response
A study participant with CAD was considered a responder if all the below criteria were met: 1. Hemoglobin level increase of ≥1.5 g/dL above baseline sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat CAD 3. Lack of treatment discontinuation
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 1 (ITP): Time to First Platelet Count ≥50 k/μL
The first time that a participant had a platelet count ≥50 k/μL after first dose of study treatment. Time to the first response was assessed for responders only.
Time frame: Up to 12 weeks (Part A)
Cohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline
The first time that a participant had a hemoglobin level ≥1.5 g/dL above baseline after first dose of study treatment. Time to the first response was assessed for responders only.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 1 (ITP): Duration of Time During Which Platelet Count Remains ≥50 k/μL Without the Use of Rescue Therapy
The duration of response corresponds to the duration of time during which a participant's platelet count remains ≥50 k/μL without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.
Time frame: Up to 12 weeks (Part A)
Cohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy
The duration of response corresponds to the duration of time during which a participant's hemoglobin level remained ≥1.5 g/dL above baseline without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 1 (ITP): Magnitude of Platelet Count Increase From Baseline
The magnitude of increase in platelet count compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: absolute platelet counts increase \<50, ≥50 and \<100, ≥100 and \<150, and ≥150 k/uL. This endpoint is only applicable to participants without rescue therapy in the treatment period.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 2 (CAD): Magnitude of Hemoglobin Increase From Baseline
The magnitude of increase in hemoglobin level compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: Hb increase from baseline by \<1, ≥1 and \<1.5, ≥1.5 and \<2, and ≥2 g/dL. This endpoint is only applicable to participants without rescue therapy in the treatment period.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 1 (ITP): Need for Rescue Therapy During Part A
Rescue therapy was defined as any therapy with ITP indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For ITP, rescue therapy generally consisted of corticosteroids, intravenous immunoglobulins or anti-Rho(D) immunoglobulin and may had been indicated in case of worsening thrombocytopenia and/or signs or symptoms of bleeding.
Time frame: Up to 12 weeks (Part A)
Cohort 2 (CAD): Need for Rescue Therapy During Part A
Rescue therapy was defined as any therapy with CAD indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For CAD, rescue therapy generally consisted of plasmapheresis, intravenous immunoglobulins (IVIG) and/or red blood cell transfusions and may had been indicated in case of worsening anemia and/or critical hemolysis.
Time frame: Up to 12 weeks (Part A)
Cohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH)
LDH was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 2 (CAD): Change From Baseline in Total Bilirubin
Total bilirubin was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 2 (CAD): Change From Baseline in Reticulocyte Count
Reticulocyte count was measured in blood samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 2 (CAD): Change From Baseline in Haptoglobin
Haptoglobin was measured in serum or plasma samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
Time frame: Baseline, up to 12 weeks (Part A)
Cohort 1 and 2: Number of Participants With AEs and SAEs During the On-treatment Period in Part A and B
Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study drug up to 7 days after the last administration of study drug.
Time frame: From first dose of study treatment to 7 days after last dose, up to approximately 43 weeks (Cohort 1) and 103 weeks (Cohort 2)
Cohort 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Iptacopan
Pharmacokinetic (PK) parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Cohort 1 and 2: Time to Maximum Observed Plasma Concentration (Tmax) of Iptacopan
PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Cohort 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Iptacopan
PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for area under the curve (AUC) calculation.
Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Cohort 1 and 2: Trough Plasma Concentration (Ctrough) of Iptacopan
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
Time frame: Pre-dose on Day 15, 29 and 57 of Part A
Participants took part in 8 investigative sites in 6 countries.
| Milestone | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Started | 9 | 10 |
| Pd analysis set | 8 | 10 |
| Itp - sc5b-9 low | 5 | 0 |
| Itp - sc5b-9 high | 4 | 0 |
| Completed | 4 | 9 |
| Not completed | 5 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Subject decision | 1 | 0 |
| Milestone | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Started | 1 | 8 |
| Itp - sc5b-9 high | 1 | 0 |
| Itp - sc5b-9 low | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 1 | 8 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 6 |
A study participant with ITP was considered a responder if all the below criteria were met: 1. Platelet count of ≥50 k/μL sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat ITP 3. Lack of treatment discontinuation
| Participants | Cohort 1 (ITP) - sC5b-9 High | Cohort 1 (ITP) - sC5b-9 Low | Cohort 1 (ITP) |
|---|---|---|---|
| Cohort 1 (ITP): Number of Participants With a Clinically Meaningful Response | 0 | 0 | 0 |
A study participant with CAD was considered a responder if all the below criteria were met: 1. Hemoglobin level increase of ≥1.5 g/dL above baseline sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat CAD 3. Lack of treatment discontinuation
| Participants | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Number of Participants With a Clinically Meaningful Response | 5 |
The first time that a participant had a platelet count ≥50 k/μL after first dose of study treatment. Time to the first response was assessed for responders only.
No measurements were reported for this outcome.
The first time that a participant had a hemoglobin level ≥1.5 g/dL above baseline after first dose of study treatment. Time to the first response was assessed for responders only.
| days | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline | 29.0 (23 to 63) |
The duration of response corresponds to the duration of time during which a participant's platelet count remains ≥50 k/μL without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.
No measurements were reported for this outcome.
The duration of response corresponds to the duration of time during which a participant's hemoglobin level remained ≥1.5 g/dL above baseline without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.
| days | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy | 56.0 (28 to 63) |
The magnitude of increase in platelet count compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: absolute platelet counts increase \<50, ≥50 and \<100, ≥100 and \<150, and ≥150 k/uL. This endpoint is only applicable to participants without rescue therapy in the treatment period.
| Participants | Cohort 1 (ITP) - sC5b-9 High | Cohort 1 (ITP) - sC5b-9 Low | Cohort 1 (ITP) |
|---|---|---|---|
| Absolute platelet counts increase <50 k/uL | 1 | 2 | 3 |
| Absolute platelet counts increase >=50 k/uL and <100 k/uL | 0 | 0 | 0 |
| Absolute platelet counts increase >=100 k/uL and <150 k/uL | 0 | 0 | 0 |
| Absolute platelet counts increase >=150 k/uL | 0 | 0 | 0 |
The magnitude of increase in hemoglobin level compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: Hb increase from baseline by \<1, ≥1 and \<1.5, ≥1.5 and \<2, and ≥2 g/dL. This endpoint is only applicable to participants without rescue therapy in the treatment period.
| Participants | Cohort 2 (CAD) |
|---|---|
| Hb increase by <1.0 g/dL | 2 |
| Hb increase by >=1.0 g/dL and <1.5 g/dL | 1 |
| Hb increase by =>1.5 g/dL and <2 g/dL | 2 |
| Hb increase by =>2 g/dL | 4 |
Rescue therapy was defined as any therapy with ITP indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For ITP, rescue therapy generally consisted of corticosteroids, intravenous immunoglobulins or anti-Rho(D) immunoglobulin and may had been indicated in case of worsening thrombocytopenia and/or signs or symptoms of bleeding.
| Participants | Cohort 1 (ITP) - sC5b-9 High | Cohort 1 (ITP) - sC5b-9 Low | Cohort 1 (ITP) |
|---|---|---|---|
| No | 1 | 2 | 3 |
| Yes | 2 | 3 | 5 |
Rescue therapy was defined as any therapy with CAD indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For CAD, rescue therapy generally consisted of plasmapheresis, intravenous immunoglobulins (IVIG) and/or red blood cell transfusions and may had been indicated in case of worsening anemia and/or critical hemolysis.
| Participants | Cohort 2 (CAD) |
|---|---|
| No | 9 |
| Yes | 1 |
LDH was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
| Units/liter (U/L) | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH) | -277.83 ± 88.966 |
Total bilirubin was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
| micromole/liter (μmol/L) | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Change From Baseline in Total Bilirubin | -15.63 ± 12.979 |
Reticulocyte count was measured in blood samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
| reticulocytes * 10^9/liter | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Change From Baseline in Reticulocyte Count | -37.45 ± 17.205 |
Haptoglobin was measured in serum or plasma samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.
| gram/liter (g/L) | Cohort 2 (CAD) |
|---|---|
| Cohort 2 (CAD): Change From Baseline in Haptoglobin | 0.12 ± 0.236 |
Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study drug up to 7 days after the last administration of study drug.
| Participants | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| AEs | 7 | 9 |
| Treatment-related AEs | 2 | 3 |
| Severe AEs | 1 | 0 |
| Treatment-related severe AEs | 1 | 0 |
| SAEs | 0 | 1 |
| Treatment-related SAEs | 0 | 0 |
| Fatal SAEs | 0 | 0 |
| Treatment-related fatal SAEs | 0 | 0 |
Pharmacokinetic (PK) parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
| ng/mL | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Day 15 | 3190.0 ± 465.00 | 4800.0 ± 838.00 |
| Day 57 | 2940.0 ± 1020.00 | 4420.0 ± 1300.00 |
PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.
| hours | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Day 15 | 2 (0.75 to 5.15) | 1 (1 to 2) |
| Day 57 | 2 (2 to 2) | 1.97 (1 to 2) |
PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for area under the curve (AUC) calculation.
| hr*ng/mL | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Day 15 | 24200.0 ± 6110.00 | 31100.0 ± 5830.00 |
| Day 57 | 21300.0 ± 5280.00 | 28200.0 ± 6880.00 |
Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.
| ng/mL | Cohort 1 (ITP) | Cohort 2 (CAD) |
|---|---|---|
| Day 15 | 1670.0 ± 1320.00 | 1980.0 ± 1720.00 |
| Day 29 | 1670.0 ± 927.00 | 1330.0 ± 337.00 |
| Day 57 | 1680.0 ± 758.00 | 1410.0 ± 320.00 |
Collected over From first dose of study treatment to 30 days after last dose, up to approximately 46 weeks (Cohort 1) and 106 weeks (Cohort 2). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (ITP) | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Cohort 2 (CAD) | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| All Patients | 0/19 (0%) | 2/19 (10.5%) | 16/19 (84.2%) |
| Event | Cohort 1 (ITP) | Cohort 2 (CAD) | All Patients |
|---|---|---|---|
| Haemorrhage intracranialNervous system disorders | 1/9 | 0/10 | 1/19 |
| HeadacheNervous system disorders | 1/9 | 0/10 | 1/19 |
| Blood creatinine increasedInvestigations | 0/9 | 1/10 | 1/19 |
| Acute kidney injuryRenal and urinary disorders | 0/9 | 1/10 | 1/19 |
| Event | Cohort 1 (ITP) | Cohort 2 (CAD) | All Patients |
|---|---|---|---|
| PetechiaeSkin and subcutaneous tissue disorders | 3/9 | 0/10 | 3/19 |
| AstheniaGeneral disorders | 0/9 | 3/10 | 3/19 |
| HeadacheNervous system disorders | 2/9 | 3/10 | 5/19 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/9 | 0/10 | 2/19 |
| ConstipationGastrointestinal disorders | 0/9 | 2/10 | 2/19 |
| NauseaGastrointestinal disorders | 1/9 | 2/10 | 3/19 |
| PyrexiaGeneral disorders | 0/9 | 2/10 | 2/19 |
| NasopharyngitisInfections and infestations | 0/9 | 2/10 | 2/19 |
| Respiratory tract infectionInfections and infestations | 0/9 | 2/10 | 2/19 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 2/10 | 2/19 |
| Age, Continuous(years) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| Mean | 44.2 ± 20.77 | 66.7 ± 10.01 | 56.1 ± 19.36 |
| Age, Customized(Participants) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| 18 - <65 years | 7 | 5 | 12 |
| 65 - <85 years | 2 | 5 | 7 |
| Sex: Female, Male(Participants) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| Female | 5 | 10 | 15 |
| Male | 4 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| Asian | 3 | 0 | 3 |
| White | 6 | 10 | 16 |
| Platelets(platelets*10^9/liter) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| Mean | 14.6 ± 10.53 | — | 14.6 ± 10.53 |
| Hemoglobin(gram/liter) | Cohort 1 (ITP) | Cohort 2 (CAD) | Total |
|---|---|---|---|
| Mean | — | 86.7 ± 9.06 | 86.7 ± 9.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from applicable studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2021 to primary completion in Sep 2023, 20 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion. A results delay was requested in Jun 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan
Purpura, Thrombocytopenic, Idiopathic →